Ferring Pharmaceuticals is to open a state-of-the-art manufacturing hub in Finland to meet supply demand for Adstiladrin (nadofaragene firadenovec-vncg). The 25,000 square metre site in Kuopio, Finland will feature a cutting-edge manufacturing suite, fully integrated with modern technology to produce adenovirus vector-based gene therapy drug substance in large quantities. Ferring is also committing to limit environmental impacts via renewable energy solutions such as waste heat recovery with heat pumps and solar energy.

Adstiladrin, (nadofaragene firadenovec-vncg) is a gene therapy for patients with non-muscle invasive bladder cancer (NMIBC). Adstiladrin is approved in the U.S. for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumours. Demand for this drug is expected to increase, as bladder cancer is now the ninth most diagnosed cancer globally.

In addition to the proposed European innovations, Ferring has further strengthened and diversified its supply chain of this drug, having also nearly completed the construction of a new manufacturing facility at Ferring’s U.S. campus in Parsippany, New Jersey.